Exopharm Ltd

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines.
While exosomes are produced readily by cultured cells, the development of exosomes as medicines has been hampered by the challenge of purifying exosomes. Exopharm owns a purification technology called LEAP, which in addition to associated manufacturing know-how, places Exopharm as a global leader for exosome technologies in this emerging field.
Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.
Exopharm uses variations and combinations of LOAD and EVPS to enable its partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems.
Ticker:
EX1
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Plexaris
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Commercial Officer
Exopharm Ltd